Chairman's Profile
Being different and making a difference. That sums up the vision, philosophy, conviction and driving force behind Dr. Habil F Khorakiwala who revels in venturing down the road less travelled.
He founded Wockhardt in 1967. Today, the Wockhardt Group is India’s leading research-based, global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology, Active Pharmaceutical Ingredients (APIs), and Super Speciality Hospitals.
Investor Information
Our investors, Wockhardt shareowners, are an important and valued constituent of the Wockhardt stakeholder universe.
While it is a matter of regulatory compliance, we also consider it as good governance and our duty and responsibility, to keep our investors informed and updated regularly about news, events and developments that impact our business and operations.
Investor Focus
About Us
Wockhardt is a leading, research-based, global enterprise with relevance in the fields of pharmaceuticals, biotechnology, and healthcare services.
Our multinational R&D and manufacturing facilities are spread across India, USA, UK and UAE, and our worldwide marketing presence includes over 30 countries across 6 continents.
Our Products
-
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium 5000 I.U./ml (previously known as Multiparin
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More
-
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium 5000 I.U./ml (previously known as Multiparin
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More
Media & Press
Team Wockhardt
OUR DISCOVERY. ROAD TO RECOVERY.
Life threatened globally by rising multidrug-resistant
infections or Antimicrobial Resistance (AMR).
WCK 5222 administered on compassionate ground and
saved over 35 lives. Now in Global phase III clinical trial.
Research Wins. Life Wins.
Life Wins
Global Reach
Media Coverage
Voice of Wockhardians
My incredible 30-year journey with Wockhardt has been nothing short of phenomenal. Over the years, I have progressed from a Territory Manager to a Vice President, paralleling the organization’s own growth and success.
GOUTAM CHAKRABORTY
Vice President – Sales & Marketing Pharma Merind
At Wockhardt, I’ve found not only a fulfilling career but also a second family. The supportive and nurturing atmosphere cultivated by our Chairman has truly inspired me and my colleagues.
VIJAY MHATRE
Manager – Finance
Working at Wockhardt for over a decade, I’ve had a fulfilling experience, with diverse roles and projects that contributed to personal and professional growth.
JAGMOHAN SINGH RISHI
Head – Training, SFE & Digital Marketing, Sales Training
As the leader of the Drug Regulatory Affairs function for the Pharmaceuticals Business at our company, my primary responsibility is to guide the organization through the regulatory process to ensure successful translation of drug research and development into medicines for patients.
ZOHER SIHORWALA
Senior Vice President and Head – Drug Regulatory Affairs
My journey with this wonderful organization began on the 25th of October, 2000. As a Manager of Marketing at The Benchmark, I had the privilege of meeting numerous prominent industrialists in Aurangabad through our exclusive membership invitations.
MONISHA BRAHMA
Associate Vice President – Administration
I have been associated with Wockhardt since 2014. I have seen Wockhardt growing wonderfully to an amazing workplace.
KAVITA TUPLONDHE
Executive Assistant to President – India Branded Business, Quality Generics, CMS & Global API
My ten-year tenure with Wockhardt, a global pioneer in pharmaceuticals and biotechnology, has been a remarkable journey of growth and learning.
PRAVIN SAMBREY
Country Manager, International Marketing ROW
Beyond Pharmaceuticals
6 new drugs under development, accorded QIDP status by US FDA and in Phase III clinical stage, are being developed as novel antibiotics and are expected to significantly aid global efforts against Antimicrobial Resistance (AMR).
A chain of super-speciality hospitals offering world-class tertiary and quaternary healthcare services, Wockhardt Hospitals has built a reputation for quality, professionalism and positive outcomes.
A chain of super-speciality hospitals offering world-class tertiary and quaternary healthcare services, Wockhardt Hospitals has built a reputation for quality, professionalism and positive outcomes.